Trial Profile
Effect of ruxolitinib in myelofibrosis patients with low and intermediate-1 risk
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Apr 2015
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 28 Apr 2015 New trial record